(Q82964583)
Statements
Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis (English)
Sarah Krausz
Maria J H Boumans
Danielle M Gerlag
Joelle Lufkin
Arno W R van Kuijk
Alian Bakker
Maarten de Boer
Beatrijs M Lodde
Kris A Reedquist
Eric W Jacobson
Michael O'Meara
14 December 2011